Phase 4 PTSD Trial, Recruiting NCT06852469 Sponsor: VA Office of Research and Development Condition: PTSD
Back to Ptsd

Phase 4 PTSD Trial, Recruiting

NCT06852469
Recruiting Phase 4

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who are military veterans
  • People between the ages of 18 and 65 (inclusive)
  • People who are willing to avoid alcohol for 24 hours before and 24 hours after the study session
  • People who are willing to give written consent and follow the study's requirements
  • (For the PTSD group only) People with a current diagnosis of PTSD, confirmed using a standardised clinical assessment called the CAPS-5

Who may not be able to join:

  • People with serious or uncontrolled medical conditions affecting the brain, heart, lungs, liver, kidneys, digestive system, immune system, hormones, or mental health, where these could affect study results or participation (confirm with trial site)
  • People who are pregnant (assessed by urine test) or currently breastfeeding
  • People with a lifetime history of a chronic psychotic disorder or bipolar disorder type I, as assessed by a clinical interview called the MINI
  • People with a current moderate or severe substance use disorder, as assessed by the MINI
  • People who test positive for drugs of abuse on a urine test at screening or before the study medication is given — though people who test positive for THC (cannabis) may have the opportunity to be retested two weeks later and could still be considered
  • People who show signs of being currently intoxicated by, or withdrawing from, drugs or alcohol
  • People who are currently taking benzodiazepine or opioid medications; other mental health medications may be allowed if the dose has been stable for at least two weeks and there is no unsafe interaction with the study medication (confirm with trial site)
  • People taking any other medication that the study doctor considers unsafe to combine with lorazepam (the study medication)
  • People who have previously had an intolerance or allergic reaction to lorazepam or any other benzodiazepine medication
  • People with active thoughts of suicide, or who are considered at high risk of suicide based on a clinical assessment
  • People with a history of traumatic brain injury that caused loss of consciousness for more than 30 minutes
  • People who do not have a sufficient command of English, or who have any other difficulty that would prevent them from understanding consent forms or completing study procedures
  • People whom the study doctor considers unsuitable for any other medical or safety reason
  • (For the healthy comparison group only) People with any Axis I mental health disorder, as assessed by the MINI (confirm with trial site)
  • (For participants taking part in brain scanning/fMRI only) People who cannot safely have an MRI scan
  • (For participants taking part in brain scanning/fMRI only) People who are not right-handed, as assessed by a standard handedness questionnaire

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 26 July 2026
Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.

Contact this trial

Principal Investigator: Jonathan R Howlett, MD, VA San Diego Healthcare System, San Diego, CA

Phone: (858) 642-1256

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 4
Registry
ClinicalTrials.gov
Start date
1 July 2025
Est. completion
30 June 2029

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Dynamic inhibition during sensorimotor control

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov